FDA Approves Calquence With Bendamustine and Rituximab for Previously Untreated Mantle Cell Lymphoma

The FDA has granted traditional approval to Calquence with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic stem cell transplantation.